Pfizer Inc. $PFE Shares Sold by Capital Analysts LLC

Capital Analysts LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 15.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 20,917 shares of the biopharmaceutical company’s stock after selling 3,739 shares during the period. Capital Analysts LLC’s holdings in Pfizer were worth $530,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. Northern Trust Corp boosted its stake in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after buying an additional 3,943,397 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Pfizer by 3.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company’s stock worth $1,045,351,000 after buying an additional 1,333,740 shares during the last quarter. Invesco Ltd. boosted its stake in Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock worth $767,709,000 after buying an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after buying an additional 1,846,436 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.7060 on Friday. The company has a market cap of $146.15 billion, a P/E ratio of 13.67, a PEG ratio of 0.90 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business’s 50-day simple moving average is $24.68 and its 200 day simple moving average is $24.42.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PFE shares. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Leerink Partners cut their price objective on Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a report on Wednesday, April 30th. Finally, Wolfe Research raised their price objective on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.